Edmond DE Rothschild Holding S.A. purchased a new stake in Erasca, Inc. (NASDAQ:ERAS – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 60,000 shares of the company’s stock, valued at approximately $880,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of ERAS. Nykredit A S purchased a new stake in Erasca during the second quarter worth approximately $29,000. Allworth Financial LP acquired a new position in shares of Erasca during the 2nd quarter valued at $34,000. EverSource Wealth Advisors LLC increased its holdings in Erasca by 77.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock valued at $69,000 after purchasing an additional 1,859 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Erasca in the 2nd quarter valued at $80,000. Finally, KBC Group NV acquired a new stake in shares of Erasca in the first quarter valued at about $81,000. 67.78% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Erasca
These are some of the ERAS headlines that stood out recently:
- Positive Sentiment: At the 32 mg daily dose, ERAS-0015 produced confirmed response rates of 44% in second-line-or-later pancreatic cancer patients with KRAS G12X mutations, 69% in the G12D/G12V pancreatic subgroup, and 60% in a small group of previously treated KRAS-mutant lung cancer patients. Erasca said the drug was generally well tolerated, with mostly low-grade side effects. Erasca Phase 1 data
- Neutral Sentiment: A Seeking Alpha contributor upgraded Erasca to “Buy,” citing ERAS-0015’s clinical progress and the company’s Bristol Myers Squibb collaboration. This is an individual analyst opinion, not a company announcement or a consensus rating. Seeking Alpha analysis
- Negative Sentiment: Despite the response rates, the findings are from an early-stage trial with small groups, so durability and results in larger studies remain uncertain. Coverage also highlighted unanswered questions around the data; investors may be weighing those risks against the promise. Erasca previously disclosed one fatal pneumonitis event related to ERAS-0015, despite the generally favorable safety profile reported in the update. Coverage of data questions
Erasca Price Performance
Shares of ERAS stock opened at $13.61 on Friday. The company’s fifty day moving average price is $14.77 and its two-hundred day moving average price is $15.35. The firm has a market capitalization of $4.78 billion, a P/E ratio of -13.75 and a beta of 0.68. Erasca, Inc. has a 12 month low of $2.75 and a 12 month high of $24.28.
Erasca (NASDAQ:ERAS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). On average, sell-side analysts anticipate that Erasca, Inc. will post -0.53 EPS for the current year.
Analyst Upgrades and Downgrades
ERAS has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a report on Tuesday, September 8th. Guggenheim upped their price target on Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Leerink Partners began coverage on shares of Erasca in a research report on Tuesday, November 17th. They issued an “outperform” rating and a $35.00 price objective for the company. HC Wainwright lifted their price objective on shares of Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Bank of America lifted their price objective on shares of Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.17.
Check Out Our Latest Stock Report on Erasca
Erasca Profile
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
See Also
- Five stocks we like better than Erasca
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ERAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Erasca, Inc. (NASDAQ:ERAS – Free Report).
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
